Artificial intelligence has made significant inroads in pharmaceutical research, but experts are increasingly pointing to a critical bottleneck: the absence of large-scale, high-quality patient data. Without it, AI models trained on limited or synthetic datasets struggle to make predictions that hold up in real-world clinical settings.
Drug discovery pipelines depend on AI tools to identify viable targets, predict molecular behavior, and screen compounds at speed. But the jump from lab hypothesis to patient outcome requires models to understand human biology in all its complexity, something that only comes from exposure to diverse, longitudinal patient records.
Researchers and industry figures are calling for stronger data-sharing frameworks between hospitals, biotech firms, and AI developers. The argument is straightforward: better data access does not just improve model accuracy, it could directly shorten the timeline from discovery to approved treatment.
